

NOVEL 2-SUBSTITUTED BENZOTHAZOLES: SYNTHESIS AND ANTIPROLIFERATIVE EVALUATION

Valentina Rep¹, Ljubica Glavaš Obrovac², Marijana Jukić², Silvana Raić Malić¹

¹University of Zagreb, Faculty of Chemical Engineering and Technology, Marulićev trg 19, 10000 Zagreb,

²Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, Josipa Huttlera 4, 31000 Osijek



Introduction


The benzothiazoles are constituents of bioactive heterocyclic compounds that exhibit wide spectrum of biological and pharmacological activities. Functionalization of the benzothiazole scaffold at the C-2 and C-6 positions was found to be a key determinant for their enhanced biological activity, mainly as cytostatic and antimicrobial agents. Some benzothiazole-based anticancer agents were found to target tyrosine kinase, topoisomerase, microtubule, cytochrome P450, heat shock protein 90 (Hsp90), epidermal growth factor receptor (EGFR) and apoptosis by reactive oxygen species (ROS) activation. Anticancer effects of 2-arylbenzothiazoles involved metabolic activation by cytochrome P450 to electrophilic reactive species, which generated DNA adducts in sensitive tumor cells. Therefore, 2-arylbenzothiazoles have emerged as an important pharmacophore in the development of antitumor agents. [1-4]

Table 1. *In vitro* growth inhibitory effects of synthesized compounds (22a-30a, 22b-30b, 22d-25d, and 27d-29d) on selected tumor cell lines

Compd	IC ₅₀ / μM				Compd	IC ₅₀ / μM			
	MDCK1	HeLa	CaCo-2	HuT78		MDCK1	HeLa	CaCo-2	HuT78
22a	>100	>100	>100	>100	26b	/	/	/	/
23a	87.3 ± 6.9	>100	>100	>100	27b	94.2 ± 18.4	>100	28.7 ± 6.7	>100
24a	>100	>100	>100	>100	28b	/	/	/	/
25a	>100	>100	>100	>100	29b	1.1 ± 0.0	>100	>100	>100
26a	25.8 ± 9.4	>100	89.3 ± 15.8	69.8 ± 15.5	30b	85.9 ± 15.7	>100	89.2 ± 16.8	64.7 ± 11.3
27a	>100	>100	>100	>100	22d	11.4 ± 4.5	>100	>100	>100
28a	79.3 ± 14.4	>100	>100	>100	23d	8.2 ± 1.8	>100	>100	>100
29a	6.8 ± 6.2	>100	>100	>100	24d	36.7 ± 8.0	>100	>100	>100
30a	78.0 ± 27.8	>100	>100	>100	25d	8.8 ± 1.3	>100	>100	>100
22b	/	/	/	/	27d	64.8 ± 8.5	>100	>100	>100
23b	10.1 ± 0.2	>100	>100	>100	28d	41.1 ± 7.2	82.8 ± 22.3	>100	49.6 ± 8.0
24b	65.7 ± 11.8	>100	>100	>100	29d	22.8 ± 4.9	>100	77.6 ± 43.3	>100
25b	/	/	/	/					

Biological evaluation

2-Arylbenzothiazole derivatives **22a-30a**, **22b-30b** and **22d-30d** were evaluated for their antiproliferative activity against cervix adenocarcinoma (HeLa), colon adenocarcinoma (CaCo2), T-cell lymphoma (HuT78) as well as normal Madin-Darby canine kidney fibroblast cells (MDCK1). Compound **27b**, with fluorine and pyridine substituents on aryl ring, showed marked antiproliferative activity against colon adenocarcinoma cells (IC₅₀ = 28.7 μM), while compound **28d** showed moderate activity against T-cell lymphoma cells (IC₅₀ = 49.6 μM). However, with exception of compound **27b**, tested compounds that exhibited antiproliferative activity were also cytotoxic in the non-tumor MDCK1 cell line.



Scheme 1. Synthesis of 6-substituted 2-arylbenzothiazole derivatives. Reagents and conditions: (i) Na₂S₂O₅, DMF, 100 °C, 2 h; (ii) propargyl bromide, K₂CO₃, ACN, rt, 24 h; (iii) corresponding alkyl halogenide, K₂CO₃, ACN, rt, 24 h; (iv) CuI, trimethylsilyl azide, DMF : MeOH = 1:1, 100 °C, 24h; (v) benzyl chloride, NaN₃, Et₃N, *t*-BuOH:H₂O = 1:1, rt, 12 h, Cu(OAc)₂.

Chemistry

Taking into consideration biological relevance of benzothiazole scaffold, novel 6-substituted 2-arylbenzothiazole derivatives (**22a-30a**, **22b-30b**, **22c-30c** and **22d-30d**) were synthesized with varied aromatic unit at phenyl ring with the aim to assess their influence on antiproliferative activity. Key benzothiazole intermediates (**4-12**) were obtained by condensation of 2-aminothiophenols with corresponding benzaldehydes using Na₂S₂O₅ and then converted to propargylated derivatives (**13-21**). Targeted 2-(4-alkoxyphenyl)benzothiazole derivatives (**22a-30a**, **22b-30b**) were obtained by an O-alkylation reaction. Finally 1,4-disubstituted 1,2,3-triazole benzothiazole analogues (**22c-30c**, **22d-30d**) were synthesized by copper catalysed reaction of the corresponding terminal alkynes and azides (Scheme 1).




Figure 1. Structures of most potent derivatives **27b** and **28d**

REFERENCES:

- [1] A. Irfan, et al., J. Enzyme Inhib. Med. Chem. 35 (2020) 265-279.
- [2] N. Pathak, et al., Mini-Rev. Med. Chem. 20 (2020) 12-23.
- [3] A. Kamal, et al., Expert Opin. Ther. Patents 25 (2014) 335-349.
- [4] E. E. Gurdal, et al., J. Enzyme Inhib. Med. Chem. 30 (2015) 649-654.

ACKNOWLEDGMENT:

Financial support from the Croatian Science Foundation under the project HRZZ-IP-2018-01-4682 is gratefully acknowledged.

